Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
- PMID: 32333898
- PMCID: PMC7935419
- DOI: 10.1016/S1474-4422(20)30078-8
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Abstract
Background: Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy. This study assessed the safety and efficacy of satralizumab monotherapy in patients with the disorder.
Methods: In this phase 3, double-blind, placebo-controlled, parallel-group trial, we enrolled adults aged 18-74 years with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 countries. Eligible participants had experienced at least one documented NMOSD attack or relapse in the past 12 months and had a score of 6·5 or less on the Expanded Disability Status Scale. Exclusion criteria included clinical relapse 30 days or fewer before baseline. Participants were randomly assigned (2:1) to receive satralizumab 120 mg or visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter. Taking immunosuppressants concomitantly was prohibited. The primary endpoint was time to the first protocol-defined relapse, based on the intention-to-treat population and analysed with stratification for two randomisation factors (previous therapy for prevention of attacks and nature of the most recent attack). Safety was assessed in all participants who received at least one dose of satralizumab or placebo. The double-blind phase was due to last until 44 protocol-defined relapses occurred or 1·5 years after random assignment of the last patient enrolled, whichever occurred first; participants could enter an open-label phase after the occurrence of a protocol-defined relapse or at the end of the double-blind phase. The study is registered with ClinicalTrials.gov, NCT02073279.
Findings: 95 (57%) of 168 screened participants were randomly assigned to treatment (63 to satralizumab; 32 to placebo) between Aug 5, 2014, and April 2, 2017. Protocol-defined relapses occurred in 19 (30%) patients receiving satralizumab and 16 (50%) receiving placebo (hazard ratio 0·45, 95% CI 0·23-0·89; p=0·018). 473·9 adverse events per 100 patient-years occurred in the satralizumab group, as did 495·2 per 100 patient-years in the placebo group; the incidence of serious adverse events and adverse events leading to withdrawal was similar between groups.
Interpretation: Satralizumab monotherapy reduced the rate of NMOSD relapse compared with placebo in the overall trial population, with a favourable safety profile. The patient population included a ratio of aquaporin-4 antibody seropositive and seronegative patients that was reflective of clinical practice. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD.
Funding: Chugai Pharmaceutical (Roche).
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures
Comment in
-
Interleukin-6 receptor blockade for the treatment of NMOSD.Lancet Neurol. 2020 May;19(5):370-371. doi: 10.1016/S1474-4422(20)30081-8. Lancet Neurol. 2020. PMID: 32333886 No abstract available.
Similar articles
-
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747. N Engl J Med. 2019. PMID: 31774956 Clinical Trial.
-
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
-
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.Lancet Neurol. 2020 May;19(5):391-401. doi: 10.1016/S1474-4422(20)30070-3. Lancet Neurol. 2020. PMID: 32333897 Free PMC article. Clinical Trial.
-
Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.CNS Drugs. 2023 Apr;37(4):363-370. doi: 10.1007/s40263-023-00995-9. Epub 2023 Mar 18. CNS Drugs. 2023. PMID: 36933107 Review.
-
Recent advances in the treatment of neuromyelitis optica spectrum disorders.Curr Opin Rheumatol. 2021 May 1;33(3):233-239. doi: 10.1097/BOR.0000000000000791. Curr Opin Rheumatol. 2021. PMID: 33741809 Review.
Cited by
-
NMOSD and MOGAD: an evolving disease spectrum.Nat Rev Neurol. 2024 Sep 13. doi: 10.1038/s41582-024-01014-1. Online ahead of print. Nat Rev Neurol. 2024. PMID: 39271964 Review.
-
Targeting cytokine networks in neuroinflammatory diseases.Nat Rev Drug Discov. 2024 Sep 11. doi: 10.1038/s41573-024-01026-y. Online ahead of print. Nat Rev Drug Discov. 2024. PMID: 39261632 Review.
-
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).Front Neurol. 2024 Aug 13;15:1437913. doi: 10.3389/fneur.2024.1437913. eCollection 2024. Front Neurol. 2024. PMID: 39193150 Free PMC article.
-
Visual improvement in a case of neuromyelitis optica spectrum disorder-related optic neuritis after 18 months of treatment with satralizumab: A case report.Heliyon. 2024 Jul 25;10(15):e35142. doi: 10.1016/j.heliyon.2024.e35142. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39157378 Free PMC article.
-
Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance.Neurol Ther. 2024 Oct;13(5):1361-1383. doi: 10.1007/s40120-024-00640-7. Epub 2024 Jul 16. Neurol Ther. 2024. PMID: 39012406 Free PMC article.
References
-
- Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc 2017; 92: 663–79. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous